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Abstract 
Introduction: Thromboembolic diseases are leading cause of mortality accounting for an 
estimated 1 in 4 deaths all over the world. Anticoagulation remains the mainstay of 
prevention and treatment of venous thromboembolic disorders. Conventional anticoagulants 
have been efficiently used over the last decades, but their clinical use encounters safety and 
convenience issues. To overcome these limitations, research have focused on development of 
new targets for anticoagulation leading to a relatively new class of drugs, non-vitamin K 
antagonist oral anticoagulants, specifically targeting activated factor X and thrombin. 
However, the search for more potent anticoagulant agents with reduced bleeding risk is still 
continuing.  
Areas covered: In this review, we provide an overview on emerging investigational 
anticoagulant drugs targeting factor XI in the coagulation cascade. We review data about the 
role of intrinsic pathway in thrombosis and haemostasis and the rationale of different 
pharmacodynamic approaches targeting factor XI.  
Expert opinion: Recent evidence suggests that the contact pathway plays a significant role in 
thrombosis by thrombus stabilization and growth without perturbing haemostasis. Factor XI 
might be a promising drug target to develop highly effective antithrombotic therapy with 
safety bleeding profile. Most of these investigational agents are in early development phases, 
only few have reached early phase clinical trials.  
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1. Background 
Thromboembolic diseases comprising of major arterial thromboses (ischaemic heart disease 
and ischaemic stroke) and venous thromboembolism (deep venous thrombosis and pulmonary 
embolism) are the leading cause of mortality accounting for an estimated 1 in 4 deaths all 
over the world [1]. Atrial fibrillation (AF) is a known major risk factor for acute 
thromboembolic events leading to debilitating stroke [2].  
 
Anticoagulation remains the mainstay of primary and secondary prevention, as well as 
treatment of venous thromboembolic disorders. Conventional anticoagulants, i.e. heparins, 
low molecular weight heparins, vitamin K antagonists (VKA) have been efficiently used over 
the last decades, but their clinical use encounters safety and convenience issues[3]. To 
overcome these limitations, extensive research have focused on development of new targets 
for anticoagulation leading to a relatively new class of drugs, the non-vitamin K antagonist 
oral anticoagulants (NOACs), specifically targeting activated factor X and thrombin. With 
the introduction of NOACs the practice of anticoagulation has been revolutionized as these 
drugs show relative efficacy, safety and convenience compared to VKAs [4]. However the 
search for the holy grail of anticoagulation: equally efficacious anticoagulant agents    with 
increased safety profile  is still continuing [5].  
 
Current research is focusing on understanding the role of intrinsic pathway (i.e. factor XI and 
XII) in coagulation processes and investigating their potential as new drug targets to achieve 
safer anticoagulation. With recent evidence suggesting that the contact pathway may play 
significant role in thrombosis by thrombus stabilization and growth, the focus has shifted to 
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develop drugs targeting factors XI and XII. Further larger trials are needed to confirm the 
additional clinical benefits and optimise treatment strategies.   
 
2. Medical need 
Anticoagulation is essential for prevention and in the treatment of DVT and PE, and has 
further expanded to cover peri-operative thrombosis prevention resulting in significant 
reductions in postoperative morbidity and mortality [6]. AF confers a five-fold increase risk 
of stroke compared with normal sinus rhythm, with AF-related stroke more likely to be fatal 
or severely disabling. Thus, stroke prevention is the cornerstone of the management of 
patients with AF, and risk stratification aids decision-making for thromboprophylaxis [7].  
 
Despite impressive progress in drug development over the last decade, anticoagulation 
remains challenging for the clinician with the aim to achieve safety thrombosis prevention 
balanced by the potential complications and risk of bleeding. Accordingly agents with 
optimized efficacy- safety profile are needed. The requirements of new antithrombotic agents 
are summarized in Table 1.  
3. Limitations of existing treatment 
Heparins were discovered almost a century ago and followed by coumarins have been the 
gold-standard of anticoagulation pharmacy for the past 60 years; however, their limitations 
(including unpredictable interindividual response, narrow therapeutic range, frequent 
monitoring, high potential for food and drug interactions) led to development of novel agents 
targeting the coagulation cascade [8].   
 
As NOACs have proved to offer relative efficacy, safety, and convenience compared with 
VKAs in the prevention of stroke and VTE, they are increasingly used as alternatives to 
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VKAs [4]. However, a significant proportion of AF patients are not prescribed anticoagulants 
because of bleeding concerns [9]. According to a metaanalysis including all the randomized 
clinical trials conducted on the four commercially available NOACs, the annual rate of major 
bleeding is 2% to 3% and the annual rate of intracranial bleeding is 0.3-0.5% in patients with 
AF [4]. 
 
All the NOACs have relatively predictable pharmacokinetic profiles and fixed daily doses 
without requiring frequent anticoagulation monitoring. Undoubtedly NOACs have less drug 
interactions compared with VKAs, although some pharmacokinetic interactions with 
accompanying drugs and comorbidities still need to be considered [10]. Additionally all the 
NOACs are substrate for the P-glycoprotein transporter, and rivaroxaban and apixaban also 
metabolized in the liver through the CYP-dependent isozyme pathway (CYP3A4). Thus, 
competitive inhibition of P-glycoprotein or CYP3A4 pathway will result in increased plasma 
levels of NOACs. Furthermore, most NOACs have some degree of renal excretion, with the 
greatest renal dependency for dabigatran; thus, the elimination of NOACs is reduced in 
patients with impaired renal function, potentially impacting efficacy and increasing bleeding 
risk. Although the phase III trials excluded patients with severe renal impairment of a 
creatinine clearance (CrCl) <25-30 ml/min, some cohort studies have demonstrated that 
NOACs also provide effective thromboprophylaxis in AF patients with mild to moderate 
renal dysfunction (CrCl of 30-79 ml/min)[11]. Alternative pharmacologic strategies with 
lower renal dependence are needed and adverse bleeding remains the most important area of 
improvement.  
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4. Scientific rationale and current research goals 
The classical two distinct pathways of the blood coagulation cascade include the extrinsic 
pathway, initiated by tissue factor and further FVIIa driven activation of FX; intrinsic pathway 
where activation of FX is propagated by FIXa and FVIIIa.  With a more precise biochemical 
understanding of the coagulation processes, it is evident now that the extrinsic pathway is 
responsible for initiation and activation of the coagulation processes as a response to vascular 
injury; however, the role of intrinsic pathway in haemostasis is secondary [12].  
 
However the focus has been shifted to elucidate the biological role of the contact system, which 
might be a critical proinflammatory and prothrombotic mediator by activating intrinsic pathway. 
Also named as plasma kallikrein-kinin system, the contact system comprises of three serine 
proteases, coagulation factors XI and XII and plasma prekallikrein and the nonenzymatic 
cofactor, high molecular weight kininogen [13].  . The only activators of the contact system were 
thought to be the artificial sites and extracorporeal conditions for decades. Recent evidence 
suggests that negative charge macromolecules such as RNA, DNA derived from injured cells or 
activated neutrophils as well as polyphosphates derived from activated platelets are potential  
triggers of the contact system, acting as a distinct initiationof coagulation at the site of vascular 
injury in thrombo-inflammatory disorders [14][15][16][17]. While long chain polyphosphates 
indeed have been shown to activate the contact pathway, a few of the other triggers, such as short 
chain polyphosphates and neutrophil extracellular traps, are cofactors rather than triggers. In fact, 
the recent report by the Morrissey group revealed that the purification protocol used by several 
of the cited studies might have created an artefact in the measurement of activation of FXII, 
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observing that the purification columns used in the studies contained silica (a potent activator of 
FXII) [18]. These trigger mechanisms need further clarification.   
 
Factor XI is a central player in thrombin generation in the amplification phase and may lead to 
overproduction of thrombin with excessive clots formation resulting in pathologic thrombosis 
[19]. Therefore factor XI would be a favourable antithrombotic drug target without major impact 
on  haemostasis as the selective inhibition of this enzyme would leave the extrinsic and common 
pathways of coagulation intact. This concept is supported by emerging research on different 
experimental thrombosis models (factor XI, XII deficient mice) proving that the contact system 
is essential for thrombus stabilization and growth, whereas haemostasis is not affected [20][21].  
 
Current epidemiologic and clinical data show that human deficiency of FXI (haemophilia C) 
rarely causes spontaneous bleeding [22][23] and patients known with that congenital disorder are 
protected from VTE and ischaemic stroke [24]. Likewise, those with elevated levels of FXI are 
more prone to thromboembolic events, and the levels of FXI correlate with stroke risk in female 
patients on hormonal contraceptive medication [22][25]. Factor XI deficient patients rarely bleed 
spontaneously but do bleed after haemostatic challenge such as tooth extraction. Data on the role 
of FXII in thrombosis are more conflicting, as patients with partial or severe FXII deficiency are 
not protected from thromboembolic diseases; however data are limited due to the rare occurrence 
of the disease [26][22].  
 
According to epidemiological data, only factor XI deficiency is associated with bleeding 
phenotype in humans, whereas factor XII, PK and HK deficiencies are not associated with 
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impaired haemostasis, not even in case of major surgery. However the in vitro clotting defect is 
evident, as surface activation to FXII assays measuring the activity of intrinsic and common 
pathways resulted in prolonged activated partial thromboplastin time  [27]. These fundamental 
findings suggest that factor XI and XII are playing different roles in “pathologic” thrombosis and 
“physiologic” haemostasis, leading research to develop specific inhibitory drugs as potential 
anticoagulants with the lack of bleeding risk. 
 
5. Competitive environment: a review of drugs in early development phases 
Current investigational drugs specifically targeting factor XI can be divided in three categories 
based on the innovative pharmacodynamic strategies used in the process of drug development: 
Antisense oligonucleotides (ASO), Monoclonal antibodies (MAb) and aptamers or small 
molecules.  
 
ASO act by reducing the hepatic synthesis of the clotting protein through a specific binding to 
the complementary mRNA target and causing catalytic degradation. MAb are parenterally 
administered molecules with a quick onset and slow offset of action, specifically binding to 
factor XI or factor XIa and counteracting theactivation or the effect of the protein [28][29]. A 
potential advantage of these new class of drugs for clinical use could be the prolonged half-life, 
making possible a once monthly subcutaneous administration; however, in case of severe 
bleeding the reversal of the effect would be problematic unless a specific reversal agent was 
available. A third class of drugs targeting factor XI are orally administered aptamers or small 
molecules with rapid onset and offset of action, blocking the active site or inducing allosteric 
modulation of the protein. Another indirect approach is to inhibit the stimulators of contact 
pathway activation, neutralizing nucleic acids or polyphosphates [30]. 
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1. ASO targeting the intrinsic pathway  
These have been successfully investigated in several animal venous and arterial thrombosis 
models and proved to have potent thromboprophylactic effects with lowered bleeding risk 
compared to warfarin and enoxaparin [29].  
 
In a baboon thrombosis model, FXI ASO reduced FXI levels in a time- and dose-dependent 
manner and did not prolong the bleeding time, furthermore demonstrating protection from 
contact-pathway initiated thrombus propagation [31]. The safety and tolerability of FXI ASO 
therapy was evaluated in cynomologous monkeys and in a phase I double-blind study involving 
healthy volunteers [32][33].  
 
A promising drug candidate, IONIS-FXI-RX (formerly ISIS-416858), discovered and developed 
by scientists at  Ionis Pharmaceuticals, was the first agent tested in humans for the prevention of 
thromboembolic events in patients undergoing orthopaedic surgery [34]. In this open-label phase 
II study 300 elective patients undergoing total knee arthroplasty were involved and IONIS- 
416858 proved to be safe and effective compared to standard thromboprophylaxis with 
enoxaparin. Currently, IONIS- 416858 is undergoing phase II clinical testing, evaluating the 
safety, tolerability, PK and PD in patients with end-stage renal disease on haemodialysis 
(NCT02553889).  
 
2. MAbs targeting factor XI  
MAbs are antibodies designed and produced by complex biotechnological processes using a 
single clone of B cells and specifically targeting a particular antigen. Since the hybridoma 
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technique has been introduced (making it possible to obtain pure MAbs in large amounts) the 
clinical innovative therapeutic use of MAbs has been largely enhanced [35]. These agents are 
specifically binding to the coagulation protein and counteracting its activation or activity.  
Aronora Inc has developed an antibody aimed to precisely target the A2 domain of FXI, 
acquiring a different mechanism of action compared to the synthetic small molecules or the 
antibodies targeting the active site of FXIa. This MAb does not inhibit the activity of FXIa, it 
only prevents the activation of FXI by FXIIa, but not by thrombin. Withpromising results in 
preclinical studies [36][37], AB023 (Xisomab 3G3) has entered clinical trials. After completion 
of phase 1 clinical trial (NCT03097341), the drug has been progressed to a Phase 2 study 
(NCT03612856) in order to evaluate the safety and efficacy profile in patients with end stage 
renal disease on chronic hemodialysis. 
Another potential MAb drug candidate, a fully humanized IgG4 FXIa antibody, developed by 
Bayer (BAY-1213790) is currently being tested as a thromboprophylactic drug, and compared 
to enoxaparin and apixaban in patients who have undergone  knee replacement surgery 
(NCT03276143). 
 
3. Synthetic small molecules  
These promising agents target the active site of factor XI and are proved to be effective in rabbit 
and rat models [25]. Factor XI is a polypeptide molecule with a dimeric structure,  comprising of 
a trypsin-like catalytic domain and 4 apple domains, that make it similar to prekallikrein, 
however with distinguishing features on apple 3 domain, which promotes the interaction with 
thrombin generation mechanism. Due to the structural molecular similarities that the trypsin-like 
catalytic domain shares with those characterizing other coagulation factors, it is essential in the 
process of drug design to pinpoint a molecule that is highly selective for factor XI and does not 
bind to other domains [38].  
Ac
ce
pte
d M
an
us
cri
pt
 
11 
 
 
Such a target seems to be reached by an investigational factor XI inhibitor molecule, BMS-
262084, synthesized by Bristol-Mayers Squibb. BMS-262084 is a monocyclic 4-carboxy-2-
azetidinone containing, mechanism-based inactivator of the active-site of human factor XIa. This 
is known to exert an irreversible inhibition over factor XIa by acting through the formation of a 
covalent bond with the active site serine residue with a strong potency of inhibiting this specific 
step in the coagulation cascade (the half maximal inhibitory concentration, IC50 of 2.8 nM) [39]. 
Antithrombotic and haemostatic effects were tested in in- vivo rat models and BMS-262084 
proved to be highly selective compared to  other coagulation proteases. Furthermore, it has been 
proved to be more specific for human FXIa with respect to the other human serine proteases  
involved in the coagulation process, namely FXa, FIXa, FVIIa, FXIIa, plasma kallikrein and to 
factors involved in the fibrinolytic process (such as tissue plasminogen activator, urokinase and 
plasmin)with a specificity of 12000 fold over FXa and 3800 fold over thrombin [40].  
 
In an ex-vivo model BMS-262084 was studied together with apixaban and rivaroxaban, known 
FXa inhibitors [41]. Activated factor X inhibitors completely blocked tissue factor-dependent 
platelet aggregation at a concentration of 1,000 nM, whereas the studied activated factor XI 
inhibitor molecule did not affect tissue factor-induced platelet aggregation even at concentrations 
up to 10 μM. However, the same drug doubled the activated thromboplastin time at a 
concentration of 0.14 μM [39], hence such behaviour may not be attributed to insufficient 
concentration.  It is conceivable that antithrombotic effect driven by FXI inhibition may not be 
safe under-conditions where tissue factor is driving thrombosis. 
Other synthetic molecules with various chemical structures proved to be effective in inhibiting 
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FXI active site, either with an acyclic, monocyclic or bicyclic structure. As a representative of 
phenylimidazoles, also known as BMS-724296 is a molecule synthesized at Bristol-Mayers 
Squibb that contains a S)-2-phenyl-1-(4-phenyl-1H- imidazol-2-yl) ethanamine core and has a 
Ki = 0.3 nM with respect to FXI [42]. This molecule has proved antithrombotic effects in a 
rabbit AV-shunt thrombosis model. It showed  Ki = 5 nM with respect to plasma kallikrein and 
Ki = 23 nM to trypsin, however a specificity of  10000+ fold over FXa, FVIIa, FXIIa, FIXa, 
thrombin, and chymotrypsin has been observed. Whilst exerting its antithrombotic effect doubles 
the aPTT at a concentration of 1 μM whereas the prothrombin time is doubled at 40 μM.  
 
The a-ketothiazole arginine derivatives are tripeptidomimetic FXIa inhibitors, with a α-
ketothiazole moiety as a C-terminal group that exerts an irreversible inhibitory function over FXI 
by covalently binding a residue (Ser195) in its active site. Such molecules are proved to be 
effective in in vivo models showing clot size reduction without causing significant collateral 
effects and without prolonging clotting time [43]. The IC50 value of the most potent inhibitor of 
this class is 6 nM. APTT was doubled up by this compound at a concentration of 2.4 μM 
whereas a two-fold increase in Prothrombin time  was registered at 25 μM. Efficacy against 
venous thrombosis has been proven in a rat model with a dosage of 0.25 mg/kg. 
 
Tetrahydroquinoline derivatives are small bicyclic molecules acting as reversible FXI active site 
inhibitor. The most potent molecule of this class showed a FXIa Ki = 0.2 nM. It is specific 
towards FXIa with a selectivity about 1000 folds higher when compared to other enzymes; 
nonetheless, it is less sensitive when it comes to kallikrein (23 fold) and activated protein C (365 
fold). In-vitro aPTT shows EC2x of 2.2 μM, therefore it is conceivable that plays a role in the 
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intrinsic coagulation system, whereas it does not affect the prothrombin time with IC2x > 20 μM 
[44]. 
 
After showing promising early results in preclinical studies, a first small molecule drug 
candidate, BMS 986177, has recently been advanced into clinical Phase II testing in patients with 
end-stage renal disease on chronic stable hemodyalisis (NCT03000673). For more details about 
experimental drugs targeting the contact pathway, see table 2. 
 
6. Potential development issues 
Some vulnerable patient groups: very elderly, with malignant co-morbidities and advanced renal 
failure still remain an area of concern regarding anticoagulation, given that those patient 
populations were excluded from randomized controlled trials of currently available NOACs, 
therefore future new anticoagulants would address this unmet clinical need.  
 
Factor XI directed strategies are being tested as thrombosis preventive agents, a further stage of 
development would be to assess their effects and potentials in the treatment of established 
venous or arterial thrombotic disorders.  
 
These agents are compounds from heterogeneous chemical classes with different 
pharmacokinetics and pharmacodynamics which may attribute some potential clinical 
advantages to be considered in further drug development. The quick onset of action of MAbs  the 
associated long half- lives and subcutaneous administration might be more suitable  forchronic 
indications, like secondary prevention after unprovoked VTE or prevention of stroke in patients 
with AF and associated severe or end-stage kidney disease. Providing reduced frequency of 
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administration (weekly or monthly regimens) may serve as clinical benefit with favourable 
impact on medication adherence.  However, in case of severe bleeding the slow offset of action 
could be an issue, unless a reversal agent was concomitantly developed. Considering their 
advantages of specificity, efficacy, and safety, there is now widespread acceptance of mAbs as 
innovative therapeutic agents. Furthermore the associated risks of immunogenicity with 
biopharmaceutical products warrants further detailed assessment in the drug development 
process.  
 
The quick onset and offset of actions of orally administered aptamers or small molecules, 
blocking the active site of the activated FXI may offer advantages in acute settings. One of the 
most important indications for their use could be anticoagulation in patients on haemodialysis or 
patients deemed at high bleeding risk, both of them representing an unmet clinical need.    
 
 
7. Conclusion 
Bleeding complications are still causing concerns in the clinical use of current anticoagulants and 
certain vulnerable patient populations are still not safely prescribed in spite of the increasing 
armamentarium of new anticoagulants. With recent evidence suggesting that the contact pathway 
may play significant role in thrombosis by thrombus stabilization and growth, the focus has 
shifted to develop drugs targeting factor XI [45]. 
The novel pharmacologic strategies, which aim to specifically target factor XI so far, are as 
follows: (i) ASO; (ii) MAb; both strategies are aimed to act by blocking the activation or activity 
of the clotting factor, and are parenterally administered with a quick onset of action; and (iii) 
aptamers and small molecules block the active site or induce allosteric modulation of the protein 
[29][28].  
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Most of these investigational agents are in early discovery and development phases, and only one 
have reached early phase clinical trials. IONIS-416858 was tested and proved to be safe and 
effective in thromboprophylaxis after orthopaedic surgery; and currently, IONIS-416858 is 
undergoing phase II clinical testing in patients with end-stage renal disease on hemodialysis. 
  
Antisense oligonucleotides and monoclonal antibodies targeting factor XI are widely 
investigated in experimental models with proven thromboprophylactic effects. Nevertheless, 
further investigations are compulsory to prove their safety and efficacy of inhibiting the intrinsic 
system in humans and to establish which particular pharmacotherapeutic option is best to be  
targeted for further development [45]. As summarised in this review, novel therapeutics targeting 
activated factor XI might fulfil the criteria of being the “holy grail”, being an effective 
anticoagulant without any excess of bleeding compared to no antithrombotic therapy.  
 
8. Expert opinion 
Current research is focusing on understanding the biological role of the contact system, a critical 
proinflammatory and prothrombotic mediator activating the intrinsic pathway and investigating 
factor XI as a  potential new drug target to achieve safer anticoagulation. 
 
The requirements of an “ideal” anticoagulant are numerous with the main objective to attenuate 
thrombosis without perturbing haemostasis. The main focus in drug development so far was to 
generate a very efficient pharmacodynamic profile, however some other important requirements, 
like stable and predictable pharmacokinetics, lack of side effects and toxicity, fast onset and 
offset of action, availability of reversal agent, low potential for food or drug interactions, fixed 
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dosing without anticoagulation monitoring and lower renal dependence should be taken into 
consideration. 
 
After recent advances in structural and molecular biology, monoclonal antibodies and antisense 
oligonucleotides are attracting interest in drug development for various pathologies. Their unique 
pharmacodynamic profile with slow onset of action and prolonged half-life may be of benefit in 
chronic indications for anticoagulation. ASOs targeting factor XI have proved to have excellent 
safety profile in early clinical trials, making them attractive for further testing in patient with 
high bleeding risks.     
 
Various innovative pharmacodynamic approaches have been developed and tested in animal 
models. However, most of these investigational agents are in early discovery and development 
phases, only few have reached early phase clinical trials. Further studies are needed to confirm 
the potential clinical benefits and optimise treatment strategies. 
  
With recent evidence suggesting that the contact pathway plays significant role in thrombosis by 
thrombus stabilization and growth without perturbing hemostasis, factor XI might be a promising 
drug target to develop highly effective antithrombotic therapy with safer bleeding profile. 
 
All figures and tables in this article are original and have not been published before. 
 
Table 1. Requirements of new antithrombotic agents 
At least as effective as NOACs 
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Predictable response, stable pharmacokinetics 
Low potential for food or drug interactions  
Fast onset and offset of action 
Wide therapeutic range 
Oral fixed dose, no need for routine anticoagulation monitoring 
Low incidence and severity of adverse effects and bleeding 
Availability of reversal agent 
Lower renal dependence 
Cost-effective 
 
 
 
 
 
Table 2. Experimental drugs targeting factor XI 
Compound  Company  Structure  Indication  Stage of 
development  
Mechanism 
of action  
BMS-
262084 
Bristol-Mayers 
Squibb 
Monocyclic 4-
carboxy-2-
azetidinone 
Antithrombotic Pre-clinical studies Inactivator of 
the active-
site of human 
FXIa 
BMS-
724296 
Bristol-Mayers 
Squibb 
Phenylimidazoles Antithrombotic Pre-clinical studies Reversible 
binding to 
the active site 
of FXIa 
14E11 N/A 
 
 
Monoclonal 
antibody 
Animal thrombosis 
models: mouse 
carotid artery 
thrombosis model; 
baboon 
arteriovenous 
Pre-clinical studies 
Prevention of artery 
occlusion; reduced 
platelet rich 
thrombus growth and 
Specific 
binding  and 
blocking FXI 
activation by 
FXIIa  
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shunt model  
Cheng et al, 2010 
[36] 
fibrin deposition in 
collagen-coated 
grafts 
Xisomab* 
(AB022)  
humanized 
version of 
14E11 
Aronora Inc., 
NCT03097341 
Monoclonal 
antibody 
Antithrombotic Ongoing Phase I 
clinical trial  
Open label, single 
ascending dose, 
randomized, double-
blind, placebo-
controlled study to 
evaluate the safety, 
tolerability, PK and 
PD in healthy adult 
subjects 
Specific 
binding   and 
blocking FXI 
activation by 
FXIIa 
BAY 
1213790*  
 
Bayer 
Healthcare, 
NCT03276143 
Fully humanized 
IgG4 antibody 
VTE prophylaxis 
in knee 
arthroplasty, n= 
700 
 
Ongoing Phase II 
clinical trial 
FOXTROT study 
BAY 1213790 
compared to 
apixaban and 
enoxaparin 
 
Specific 
binding to 
active site of 
FXIa and  
blocking FXIa 
activity 
O1A6 N/A Monoclonal 
antibody 
Primate thrombosis 
model 
O1A6 2 mg/kg vs. 
aspirin 32 mg/kg 
for graft occlusion 
prevention; Tucker 
et al, 2009 [37] 
Pre-clinical studies 
99% inhibition of 
plasma FXIa 
activity, suppressed 
thrombin-
antithrombin 
complex formation, 
inhibited platelet and 
fibrin deposition; 
O1A6 prevented the 
occlusion of smaller-
diameter grafts 
without affecting 
bleeding times 
Specific 
binding to 
FXI and 
blocking 
activation or 
activity 
Factor XI 
ASOs 
N/A Antisense 
oligonucleotides 
Catheter 
thrombosis model 
in rabbit; Yau et al, 
2014 [46] 
Pre-clinical 
Catheter occlusion 
time increased (2.3 
fold) 
Reducing the 
hepatic 
synthesis of 
FXI 
 N/A Antisense Baboon model of 
thrombosis and 
Pre- clinical Reducing the 
hepatic 
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*Investigational drugs advanced into clinical trials  
ASO- antisense oligonucleotides; aPTT- activated prothrombin time; ESRD- end-stage renal 
disease; FXI- Factor XI; MAb- monoclonal antibody; PD- pharmacodynamics; PK- 
pharmacokinetics; VTE- venous thromboembolism. 
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